Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285632 | 0.89 | ALDH1A1 (0.35) | GAATP53KDM4EALDH1A1SCD | |
| SCHEMBL285631 | 0.89 | ALDH1A1 (0.35) | GAATP53KDM4EALDH1A1SCD | |
| SCHEMBL285811 | 0.88 | NPC1 (0.39) | GAATP53KDM4EALDH1A1SCD | |
| SCHEMBL285812 | 0.88 | NPC1 (0.39) | GAATP53KDM4EALDH1A1SCD | |
| SCHEMBL285700 | 0.87 | POLB (0.35) | GAATP53ALDH1A1SCDL3MBTL1 | |
| SCHEMBL295937 | 0.86 | GABRA5 (0.34) | GAATP53 | |
| SCHEMBL285699 | 0.86 | GABRA5 (0.43) | GAATP53KDM4EALDH1A1SCD | |
| SCHEMBL285701 | 0.86 | GABRA5 (0.43) | GAATP53KDM4EALDH1A1SCD | |
| SCHEMBL2749746 | 0.85 | ALDH1A1 (0.38) | GAATP53KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL286202 | 0.85 | ALDH1A1 (0.38) | GAATP53KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427459-B1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | claimed |
| US-8178522-B2 | Thiazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | claimed |
| US-20100286116-A1 | THIAZOLES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | claimed |
| EP-2427459-B1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2427459-B1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| US-8178522-B2 | Thiazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178522-B2 | Thiazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178522-B2 | Thiazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2427459-A1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127974-A1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127974-A1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286116-A1 | THIAZOLES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286116-A1 | THIAZOLES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286116-A1 | THIAZOLES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286116-A1 | THIAZOLES | GABRA5, GABRA1, GABRA4 | GAA 826/4885TP53 3597/4885KDM4E 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.